Cardiovascular Risk in Rheumatic Patients: The Link between Inflammation and Atherothrombosis

Abstract

In addition to a high prevalence of the metabolic syndrome and a significant under-diagnosis of vascular risk factors (VRFs), the effect of chronic inflammation also represents the cornerstone of the raised cardiovascular (CV) risk in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Moreover, the finding that among current anti-inflammatory treatments, the use of tumor necrosis factor (TNF)-α blockers is associated with optimal rheumatologic and CV outcomes further supports the impact of inflammation on the CV risk. However, up-to-date treatment guidelines suggest that TNF-α blockers should be used only after the failure of traditional disease-modifying antirheumatic drugs (DMARDs). Early predictors of the therapeutic efficacy of traditional DMARDs are needed to identify candidates for TNF-α blocker treatment. Furthermore, whether the CV risk should be taken into account while choosing antirheumatic treatments is an emerging issue to be addressed. Common educational programs for specialists and general practitioners and appropriate CV prevention programs, taking into consideration traditional VRFs as well as the inflammatory status, should be planned to prevent ischemic events and to achieve optimal inflammation control in rheumatic patients.

Keywords

cardiovascular risk - rheumatoid arthritis - psoriatic arthritis - ankylosing spondylitis

• References

• 1 Peters MJ, Symmons DP, McCarey D , et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69 (2) 325-331
• 2 Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010; 30 (5) 1014-1026
• 3 Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108 (24) 2957-2963
• 4 del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44 (12) 2737-2745
• 5 van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65 (12) 1551-1557
• 6 Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66 (9) 1132-1136
• 7 Popa C, van den Hoogen FH, Radstake TR , et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66 (11) 1503-1507
• 8 Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247 (3) 349-358
• 9 Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34 (3) 585-592
• 10 Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11 (8) 327-332
• 11 Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999; 19 (4) 972-978
• 12 Solomon DH, Karlson EW, Rimm EB , et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107 (9) 1303-1307
• 13 Liang KP, Kremers HM, Crowson CS , et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009; 36 (11) 2462-2469
• 14 Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010; 69 (9) 1649-1654
• 15 Aho K, Salonen JT, Puska P. Autoantibodies predicting death due to cardiovascular disease. Cardiology 1982; 69 (3) 125-129
• 16 Karvounaris SA, Sidiropoulos PI, Papadakis JA , et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 2007; 66 (1) 28-33
• 17 Chung CP, Oeser A, Solus JF , et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196 (2) 756-763
• 18 Toms TE, Panoulas VF, Douglas KM , et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010; 69 (4) 683-688
• 19 Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53 (8) 551-552
• 20 Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010; 8 (3) 301-326
• 21 Panoulas VF, Metsios GS, Pace AV , et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47 (9) 1286-1298
• 22 Klarenbeek NB, van der Kooij SM, Huizinga TJ , et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010; 69 (7) 1342-1345
• 23 Panoulas VF, Douglas KM, Milionis HJ , et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (9) 1477-1482
• 24 Provan SA, Semb AG, Hisdal J , et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis Feb. 2011; 70: 812-817
• 25 Mäki-Petäjä KM, Hall FC, Booth AD , et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114 (11) 1185-1192
• 26 Tanaka K, Inaba M, Goto H , et al. Paraarticular trabecular bone loss at the ultradistal radius and increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. J Rheumatol 2006; 33 (4) 652-658
• 27 Pieringer H, Schumacher S, Stuby U, Biesenbach G. Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls. Semin Arthritis Rheum 2009; 39 (3) 163-169
• 28 Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82 (6) 407-413
• 29 Park YB, Ahn CW, Choi HK , et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46 (7) 1714-1719
• 30 Kumeda Y, Inaba M, Goto H , et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46 (6) 1489-1497
• 31 Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 2011; Oct 27. DOI: 10.1016/j.semarthrit.2011.08.003
• 32 Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis?. Platelets 2008; 19 (2) 146-154
• 33 Wang F, Wang NS, Yan CG, Li JH, Tang LQ. The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol 2007; 26 (5) 768-771
• 34 Bisoendial RJ, Levi M, Tak PP, Stroes ES. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events. Semin Thromb Hemost 2010; 36 (4) 452-457
• 35 So AK, Varisco PA, Kemkes-Matthes B , et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 1 (12) 2510-2515
• 36 Undas A, Gissel M, Kwasny-Krochin B, Gluszko P, Mann KG, Brummel-Ziedins KE. Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Thromb Haemost 2010; 104 (2) 224-230
• 37 Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59 (12) 1690-1697
• 38 Peters MJ, van Halm VP, Voskuyl AE , et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61 (11) 1571-1579
• 39 Douglas KM, Pace AV, Treharne GJ , et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65 (3) 348-353
• 40 Maradit-Kremers H, Crowson CS, Nicola PJ , et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52 (2) 402-411
• 41 Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34 (5) 937-942
• 42 Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H ; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54 (8) 2665-2673
• 43 Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011; 63 (2) 195-202
• 44 Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 2011; Sep 8. doi:10.1002/acr.20627
• 45 Di Minno MN, Tufano A, Rusolillo A, Di Minno G, Tarantino G. High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol 2010; 16 (48) 6119-6122
• 46 Seitz M, Reichenbach S, Möller B, Zwahlen M, Villiger PM, Dufour JF. Hepatoprotective effect of tumor necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 2010; 69 (6) 1148-1150
• 47 Di Minno MND, Iervolino S, Peluso R , et al. Hepatic steatosis and disease activity in subjects with psoriatic arthritis on TNF-α blockers. J Rheumatol 2011; ;in press. DOI: 10.3899/jrheum.111391
• 48 Di Minno MN, Tremoli E, Coppola A, Lupoli R, Di Minno G. Homocysteine and arterial thrombosis: challenge and opportunity. Thromb Haemost 2010; 103 (5) 942-961
• 49 Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol 2001; 30 (5) 305-307
• 50 Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19 (6) 1368-1377
• 51 Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 1981; 40 (1) 66-69
• 52 Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol 2012; 39: 334-336
• 53 Kimhi O, Caspi D, Bornstein NM , et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36 (4) 203-209
• 54 Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA , et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57 (2) 287-293
• 55 Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57 (6) 1074-1080
• 56 Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. TNF-α blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med 2011; ; In press
• 57 Shoenfeld Y, Gerli R, Doria A , et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112 (21) 3337-3347
• 58 Eder L, Zisman D, Barzilai M , et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008; 35 (5) 877-882
• 59 Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G ; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011; 31: 705-712
• 60 Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40 (10) 1868-1872
• 61 Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68 (7) 1131-1135
• 62 Jamnitski A, Visman IM, Peters MJ, Boers M, Dijkmans BA, Nurmohamed MT. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis 2011; 70 (5) 875-876
• 63 Buckley C, Cavill C, Taylor G , et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol 2010; 37 (10) 2141-2144
• 64 Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000; 27 (5) 1247-1250
• 65 Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369 (9570) 1379-1390
• 66 Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011; 63 (4) 550-556
• 67 Peters MJ, Visman I, Nielen MM , et al. Ankylosing spondylitis: a risk factor for myocardial infarction?. Ann Rheum Dis 2010; 69 (3) 579-581
• 68 Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33 (11) 2167-2172
• 69 Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63 (4) 557-563
• 70 Başkan BM, Sivas F, Aktekin LA, Doğan YP, Ozoran K, Bodur H. Serum homocysteine level in patients with ankylosing spondylitis. Rheumatol Int 2009; 29 (12) 1435-1439
• 71 Gonzalez-Lopez L, Sanchez-Hernandez JD, Aguilar-Chavez EA , et al. Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables. Rheumatol Int 2008; 28 (12) 1223-1228
• 72 Wei JC, Jan MS, Yu CT , et al. Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26 (5) 739-742
• 73 Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 2005; 109 (2) 171-176
• 74 Papadakis JA, Sidiropoulos PI, Karvounaris SA , et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009; 27 (2) 292-298
• 75 van Halm VP, van Denderen JC, Peters MJ , et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65 (11) 1473-1477
• 76 van Eijk IC, de Vries MK, Levels JH , et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60 (5) 1324-1330
• 77 Gordon DJ, Rifkind BM. High-density lipoprotein—the clinical implications of recent studies. N Engl J Med 1989; 321 (19) 1311-1316
• 78 Kemény-Beke Á, Gesztelyi R, Bodnár N , et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. Joint Bone Spine 2011; 78 (2) 184-187
• 79 Erre GL, Sanna P, Zinellu A , et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 2011; 30 (1) 21-27
• 80 Sari I, Okan T, Akar S , et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45 (3) 283-286
• 81 van Eijk IC, Peters MJ, Serné EH , et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009; 68 (3) 362-366
• 82 Mathieu S, Joly H, Baron G , et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008; 47 (8) 1203-1207
• 83 Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA , et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88 (6) 358-365
• 84 Lautermann D, Braun J. Ankylosing spondylitis—cardiac manifestations. Clin Exp Rheumatol 2002; 20 (6, Suppl 28) S11-S15
• 85 Vinsonneau U, Brondex A, Mansourati J , et al. Cardiovascular disease in patients with spondyloarthropathies. Joint Bone Spine 2008; 75 (1) 18-21
• 86 Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286 (8) 954-959
• 87 Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153 (4) 477-484
• 88 Gislason GH, Rasmussen JN, Abildstrom SZ , et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169 (2) 141-149
• 89 Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 2006; 164 (9) 881-889
• 90 White WB, West CR, Borer JS , et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99 (1) 91-98
• 91 Solomon DH, Avorn J, Katz JN , et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54 (12) 3790-3798
• 92 Edwards CJ, Arden NK, Fisher D , et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 2005; 44 (11) 1394-1398
• 93 Westlake SL, Colebatch AN, Baird J , et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49 (2) 295-307
• 94 Micha R, Imamura F, Wyler von Ballmoos M , et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108 (9) 1362-1370
• 95 Moreland LW, Schiff MH, Baumgartner SW , et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130 (6) 478-486
• 96 Vis M, Nurmohamed MT, Wolbink G , et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; (32) 252-255
• 97 Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006; 365 (1–2) 143-148
• 98 Schimmel EK, Yazici Y. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. Clin Exp Rheumatol 2009; 27 (3) 446-451
• 99 Macías I, García-Pérez S, Ruiz-Tudela M, Medina F, Chozas N, Girón-González JA. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol 2005; 32 (11) 2102-2108
• 100 Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103 (13) 1813-1818
• 101 Hürlimann D, Forster A, Noll G , et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106 (17) 2184-2187
• 102 Mazzoccoli G, Notarsanto I, de Pinto GD , et al. Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med 2010; 5 (6) 495-500
• 103 Irace C, Mancuso G, Fiaschi E, Madia A, Sesti G, Gnasso A. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 177 (1) 113-118
• 104 Sidiropoulos PI, Siakka P, Pagonidis K , et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009; 38 (1) 6-10
• 105 Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010; 55 (2) 333-338
• 106 Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44 (11) 1428-1432
• 107 Del Porto F, Laganà B, Lai S , et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (7) 1111-1115
• 108 Tam LS, Li EK, Shang Q , et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 2011; 70 (4) 705-706
• 109 Jacobsson LT, Turesson C, Gülfe A , et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32 (7) 1213-1218
• 110 Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP ; British Society for Rheumatology Biologics Register Control Centre Consortium ; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56 (9) 2905-2912
• 111 Westlake SL, Colebatch AN, Baird J , et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2011; 50: 518-531
• 112 Panoulas VF, Douglas KM, Milionis HJ , et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (9) 1477-1482
• 113 Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70 (1) 8-14
• 114 Conroy RM, Pyörälä K, Fitzgerald AP , et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24 (11) 987-1003
• 115 Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97 (18) 1837-1847
• 116 Chung CP, Oeser A, Avalos I , et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8 (6) R186
• 117 Peters MJ, Symmons DP, McCarey D , et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69 (2) 325-331
• 118 National Institute for Health and Clinical Excellence. Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology. Available at: http://www.nice.org.uk/media/F72/5C/BiologicDrugsUpdateAug2011.pdf . Accessed Aug 2011
• 119 Iervolino S, Di Minno MND, Peluso R , et al. Predictors of early minimal disease activity in Psoriatic Arthritis patients treated with TNF-α blockers. J Rheumatol 2012; ;in press. DOI: 10.3899/jrheum.110763